ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 021,27
0,21%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Lineage Cell Therapeutics Inc (LCTX)

  7. Lineage Cell Therapeutics Inc (LCTX) Actualités

LCTX Lineage Cell Therapeutics Inc

1,08
0,03 (2,86%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Lineage Cell Therapeutics Inc LCTX AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,03 2,86% 1,08 01:55:09
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,09 1,05 1,12 1,06 1,05
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/3/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/3/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202423:17EDGAR2Form S-3 - Registration statement under Securities Act of..
07/3/202422:10EDGAR2Form 8-K - Current report
15/2/202423:27EDGAR2Form 8-K - Current report
13/2/202403:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202403:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202401:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202400:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202400:57EDGAR2Form SC 13D/A - General statement of acquisition of..
06/2/202415:25EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
06/2/202415:20EDGAR2Form 8-K - Current report
06/2/202415:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/1/202401:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/11/202322:21APSTake Part in the Next Generation of Spinal Cord Injury..
13/11/202322:19EDGAR2Form S-8 - Securities to be offered to employees in employee..
09/11/202322:10EDGAR2Form 8-K - Current report
11/10/202316:00APSSmall Company Working on Big Breakthrough in Treating Spinal..
07/9/202323:01EDGAR2Form 8-K - Current report
10/8/202322:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:10EDGAR2Form 8-K - Current report
27/7/202322:15EDGAR2Form ARS - Annual Report to Security Holders
27/7/202322:10EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
27/7/202322:05EDGAR2Form DEF 14A - Other definitive proxy statements
11/7/202322:05EDGAR2Form PRE 14A - Other preliminary proxy statements
03/7/202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202323:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202323:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/7/202322:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Dernières Valeurs Consultées

AMEX
LCTX
Lineage Cell Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés